Maxim Group analyst Michael Okunewitch downgrades $Gilead Sciences (GILD.US)$ to a hold rating.
According to TipRanks data, the analyst has a success rate of 34.0% and a total average return of -14.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
Gilead experienced a sales surge, attributable to robust performance throughout its HIV product lineup, coupled with higher-than-anticipated earnings from Veklury. It was observed that Gilead's HIV segment delivered a vigorous quarter, marked by sustained volume expansion and a positive product mix.
The company surpassed third-quarter expectations, bolstered not only by Veklury but also by the performance of Biktarvy.
The sentiment is that a new chapter is unfolding for Gilead, with the company breaking free from past questionable business decisions and returning to its foundational role as a pioneer in the antiviral space. This resurgence is spearheaded by lenacapavir, a promising antiviral that has the potential to become a cornerstone in HIV therapy and to broaden the application of PrEP to a wider audience. There's a belief that the PrEP market has untapped potential beyond the conventional focus on MSM and high-risk groups. Progress is also noted in oncology, with significant growth observed for TRODELVY and a collaboration with a partner that appears to possess a superior CAR-T therapy for multiple myeloma.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Maxim Group分析師Michael Okunewitch下調$吉利德科學 (GILD.US)$至持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為34.0%，總平均回報率為-14.6%。
此外，綜合報道，$吉利德科學 (GILD.US)$近期主要分析師觀點如下：
吉利德經歷了銷售額飆升，這歸功於其艾滋病毒產品系列表現強勁，再加上來自Veklury的高於預期的收入。觀察發現，吉利德的艾滋病毒領域交出了一個有活力的季度，以持續的成交量擴張和積極的產品組合爲特點。
該公司超越了第三季度的預期，不僅得益於Veklury，還得益於Biktarvy的表現。
人們對吉利德迎來一個新篇章的情緒日益高漲，公司擺脫了過去存疑的業務決策，並回歸到作爲抗病毒領域先驅的基礎角色。這種復甦是由lenacapavir主導的，這是一種頗具潛力成爲HIV治療中心的抗病毒藥物，並將PreP的應用範圍擴展到更廣泛的受衆群體。人們相信，PreP市場在傳統關注MSm和高風險人群之外還有未開發的潛力。腫瘤學領域也取得進展，TRODELVY的顯著增長以及與擁有出色CAR-t療法的合作伙伴在多發性骨髓瘤領域的合作也引起了注意。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
